Tanvee Varma
About
Research
Publications
2024
The Promise and Perils of Diversity Action Plans for Clinical Trials
Varma T, Bierer B, Hantel A. The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA 2024, 332 PMID: 39302826, DOI: 10.1001/jama.2024.18225.Peer-Reviewed Original Research
2023
Clinical Trial Diversity—Will We Know It When We See It?
Varma T, Gross C, Miller J. Clinical Trial Diversity—Will We Know It When We See It? JAMA Oncology 2023, 9: 765-767. PMID: 37022678, DOI: 10.1001/jamaoncol.2023.0143.Peer-Reviewed Original ResearchData transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
Liu J, Jayaram G, Varma T, Sammut S, Guerra C, Miller J. Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021. Journal Of Clinical Oncology 2023, 41: 1594-1594. DOI: 10.1200/jco.2023.41.16_suppl.1594.Peer-Reviewed Original ResearchPivotal trialsDrug approval packagesClinical trialsApproval packagesNovel cancer therapeuticsDemographic dataCancer therapeuticsUS cancer populationUS Cancer StatisticsCross-sectional studyOncology clinical trialsPercentage of participantsClinical trial infrastructurePercentage of trialsCancer populationProportion of trialsCancer statisticsDrug AdministrationOncology drugsTrial infrastructureCancer typesData reportingU.S. FoodOlder adultsTrialsRanking pharmaceutical companies on clinical trial diversity
Varma T, Miller J. Ranking pharmaceutical companies on clinical trial diversity. The BMJ 2023, 380: p334. PMID: 36764687, DOI: 10.1136/bmj.p334.Peer-Reviewed Original Research
2022
Physician-Legislators in Federal and State Government in 2022
Varma T, Goldenberg M. Physician-Legislators in Federal and State Government in 2022. JAMA 2022, 328: 2450-2452. PMID: 36342708, PMCID: PMC9641586, DOI: 10.1001/jama.2022.20830.Peer-Reviewed Original ResearchDiversity in clinical research: public health and social justice imperatives
Varma T, Jones CP, Oladele C, Miller J. Diversity in clinical research: public health and social justice imperatives. Journal Of Medical Ethics 2022, 49: 200-203. PMID: 35428737, DOI: 10.1136/medethics-2021-108068.Peer-Reviewed Original Research
2021
Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatientsEquitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover
Zaidi D, Miller J, Varma T, Boatright D, Friesen P. Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover. The American Journal Of Bioethics 2021, 21: 86-88. PMID: 33616486, DOI: 10.1080/15265161.2020.1870768.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News & Links
News
- December 18, 2022Source: Bloomberg Law
Congress Should Take This Chance to Fix Clinical Trial Diversity
- November 07, 2022Source: JAMA
Physician-Legislators in Federal and State Government in 2022
- October 19, 2021
Speaking Out for “Medicare for All”